Back to today’s briefing

Story perspectives

Novo Nordisk Faces Backlash Over Pharmacy Sponsorship Deals

1/8/2025

40 8

Summary

Story summary

Novo Nordisk A/S is under fire for its sponsorship agreements with UK pharmacies, igniting ethical debates about conflicts of interest in drug advertising. In a bid to innovate, the company has also joined forces with Variant Bio, committing up to $50 million to delve into genetic targets for metabolic diseases, promising a brighter future for diverse treatment options.

1 of 1

Story summary

Novo Nordisk A/S is under fire for its sponsorship agreements with UK pharmacies, igniting ethical debates about conflicts of interest in drug advertising. In a bid to innovate, the company has also joined forces with Variant Bio, committing up to $50 million to delve into genetic targets for metabolic diseases, promising a brighter future for diverse treatment options.